BioWorld - Friday, May 1, 2026
Breaking News: Read BioWorld's AACR 2026 coverageBreaking News: Axsome’s Auvelity cleared for large Alzheimer’s agitation marketBreaking News: Best of BioWorld: Q1

BioWorld Science
BioWorld Science RSS Feed RSS

Test tubes, dropper
Endocrine/metabolic

Astrazeneca’s AZD-6234 prompts body weight loss due to reduced food intake

Sep. 18, 2024
Amylin is a hormone co-secreted with insulin in the pancreas that has anorexigenic effects, since it promotes satiety and reduces food intake. Amylin analogs and dual agonists of the amylin and calcitonin receptors have been developed for treating obesity. Astrazeneca plc reported results with their AMYR3 agonist AZD-6234.
Read More
Cancer

CID-078 has activity in small, non-small-cell lung cancer models

Sep. 18, 2024
Researchers from Circle Pharma Inc. have presented preclinical data for CID-078, a novel orally bioavailable cyclin A/B Rxl macrocycle being developed for the treatment of patients with lung cancer. CID-078 was developed as a macrocycle that binds to the hydrophobic patch of cyclins A and B and blocks RxL-dependent interactions of proteins, such as that of E2F1 with cyclin A-CDK2 and Myt1 with cyclin B-CDK1.
Read More
Red blood cell infected with malaria parasites
Infection

Novartis synthesizes fast-acting intravenous agents for malaria

Sep. 18, 2024
The increasing resistance to intravenous artemisinin therapy for malaria highlights the urgent need for new treatments that offer better patient compliance and a single-dose cure to address this global health threat. Novartis AG recently presented the discovery, development and evaluation of aminoisoquinolines as fast-acting intravenous therapeutic agents for severe malaria treatment.
Read More
Endocrine/metabolic

RKER-065 fights fat, preserves muscle in mice on semaglutide

Sep. 18, 2024
Incretin therapies based on GLP-1 receptor agonism aid in the loss of weight in obesity, but a relevant part of this loss (25%-40%) is attributed to loss of lean muscle mass, which raises the risk of sarcopenia. Keros Therapeutics Inc. has presented data on RKER-065, a novel modified ActRII-Fc ligand trap that inhibits myostatin and activins and promotes muscle formation.
Read More